Diabetes: Medtronic launches ‘Pattern Snapshot’ for iPro2 CGM

Medtronic (NYSE:MDT) said today that it launched a new “Pattern Snapshot” report for its iPro2 professional continuous glucose monitor that’s designed to give healthcare providers a 1-page overview of a patient’s glucose data trends.

The Pattern Snapshot report, part of Fridley, Minn.-based Medtronic’s CareLink iPro diabetes management software, is designed to identify the top 3 patterns in a patient’s blood glucose levels that could indicate glucose control issues and causes. The iPro2 device is designed to record glucose levels 24 hours a day for 3 days, Medtronic said.

“We developed this rule-based, simplified report to enhance the use of professional CGM as part of the overall diabetes management regimen,” non-intensive diabetes therapies general manager Laura Stoltenberg said in prepared remarks. “HCPs will now have a simplified report that will allow for faster interpretation of the most important diabetes metrics, so they can quickly uncover their patient’s most important issues.”

“The retrospective CGM technology of Medtronic’s iPro2 professional CGM presents the patient and provider with accurate information that allows personalized treatment decisions. This comprehensive yet easy-to-interpret continuous glycemic data will arm the care team with valuable and previously difficult to obtain data,” added Dr. Todd Zeiger of Cincinnati’s UH Primary Care Institute.

The post Diabetes: Medtronic launches ‘Pattern Snapshot’ for iPro2 CGM appeared first on MassDevice.

from MassDevice http://ift.tt/1lq9NOF